Geode Capital Management LLC Buys 34,032 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Geode Capital Management LLC raised its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 4.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 803,531 shares of the biotechnology company’s stock after buying an additional 34,032 shares during the period. Geode Capital Management LLC’s holdings in CytomX Therapeutics were worth $948,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Acadian Asset Management LLC raised its stake in CytomX Therapeutics by 1.4% during the 2nd quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company’s stock worth $3,324,000 after buying an additional 37,739 shares during the period. XTX Topco Ltd raised its stake in CytomX Therapeutics by 382.6% during the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after buying an additional 48,033 shares during the period. Sei Investments Co. acquired a new position in CytomX Therapeutics during the 2nd quarter worth approximately $467,000. Cubist Systematic Strategies LLC raised its stake in CytomX Therapeutics by 96.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after buying an additional 40,309 shares during the period. Finally, Forefront Analytics LLC raised its stake in CytomX Therapeutics by 206.7% during the 2nd quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock worth $78,000 after buying an additional 43,176 shares during the period. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Stock Down 10.4 %

Shares of CytomX Therapeutics stock opened at $0.88 on Friday. The company has a market cap of $68.88 million, a PE ratio of 5.18 and a beta of 1.03. CytomX Therapeutics, Inc. has a 52 week low of $0.83 and a 52 week high of $5.85. The business has a 50 day moving average price of $1.05 and a 200-day moving average price of $1.17.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.23. The firm had revenue of $33.43 million during the quarter, compared to the consensus estimate of $18.92 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same period in the prior year, the business posted $0.04 earnings per share. As a group, research analysts anticipate that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, CytomX Therapeutics presently has an average rating of “Hold” and a consensus target price of $5.77.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.